Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
For decades, effective treatment for metastatic colorectal cancer (mCRC) was an almost impenetrable obstacle, with a single therapeutic option—fluorouracil. Outcomes were highly consistent across time and across trials, with a median overall survival (OS) of approximately 1 year. The last 20 years have seen highly clinically relevant improvements in not only OS but also progression-free survival (PFS) and response rates. In the most recently reported large first-line randomized trials, median OS has reached or exceeded 30 months.1
Sargent D. Improved Outcomes in Metastatic Colon Cancer: Giving Credit Where Credit Is Due. JAMA Oncol. 2015;1(6):795–796. doi:10.1001/jamaoncol.2015.1789
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: